PubRank

Lorena Baietto

Author PubWeight™ 27.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. J Chromatogr Sci 2008 1.33
2 Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. Antimicrob Agents Chemother 2011 1.24
3 Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008 1.22
4 An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008 1.18
5 Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 2010 1.03
6 HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci 2007 0.94
7 A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J Pharm Biomed Anal 2010 0.92
8 Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet 2008 0.91
9 HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. J Pharm Biomed Anal 2010 0.89
10 Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. Ther Drug Monit 2012 0.88
11 Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Antivir Ther 2011 0.87
12 Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet Genomics 2010 0.87
13 A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther Drug Monit 2010 0.85
14 Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. Antimicrob Agents Chemother 2007 0.85
15 Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. J Antimicrob Chemother 2010 0.83
16 Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br J Clin Pharmacol 2012 0.83
17 A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. J Chromatogr B Analyt Technol Biomed Life Sci 2006 0.80
18 Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. J Pharm Biomed Anal 2012 0.80
19 Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther Drug Monit 2012 0.79
20 Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. Int J Antimicrob Agents 2013 0.79
21 New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009 0.79
22 Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. J Antimicrob Chemother 2012 0.79
23 Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Ther Drug Monit 2012 0.78
24 Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. Liver Int 2013 0.78
25 A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab 2014 0.78
26 Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. Clin Chem Lab Med 2015 0.77
27 Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. J Chemother 2013 0.77
28 Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. J Antimicrob Chemother 2015 0.77
29 Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. Antivir Ther 2014 0.76
30 Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. Ther Drug Monit 2012 0.76
31 Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. Pharmacogenomics 2014 0.76
32 Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. Hepatology 2011 0.75
33 Ultra performance liquid chromatography PDA method for determination of tigecycline in human plasma. Ther Drug Monit 2013 0.75
34 A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. Ther Drug Monit 2008 0.75
35 Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. Scand J Infect Dis 2013 0.75
36 HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). J Pharm Biomed Anal 2011 0.75
37 Ceftriaxone bone penetration in patients with septic non-union of the tibia. Int J Infect Dis 2011 0.75